Pharmidea

Pharmidea is a pharmaceutical company based in Latvia that focuses on the development, manufacturing, and registration of sterile pharmaceuticals, particularly generics for various therapeutic areas. Founded in 2005 in Olaine, Latvia, Pharmidea specializes in sterile pharmaceuticals. The company has undergone a strategic focus on generic medications and has completed one investment deal, raising undisclosed funding from Eko Investors in June 2008. Pharmidea specializes in the development, manufacturing, and registration of sterile pharmaceuticals, primarily focusing on generic medications across various therapeutic areas, including oncology, obstetrics, antifungal treatments, cardiology, and anesthesia.

The company's core product offerings are sterile drugs packaged in vials, produced using advanced technological methods such as lyophilization, aseptic filling, and autoclaving. Targeting healthcare providers, hospitals, and pharmaceutical distributors, Pharmidea serves a global client base across over 60 countries, including markets in Europe, Asia, and the Middle East. The company adheres to stringent quality standards set by the European Union and ensures that its products meet the regulatory requirements of diverse international markets, effectively addressing the specific needs of its clients while facilitating approval and commercialization. In 2023, Pharmidea reported a revenue of USD 8.

05 mn and an EBITDA of USD 1. 46 mn. The company generates revenue through the production and sale of sterile pharmaceuticals, primarily via business-to-business transactions with healthcare providers, hospitals, and pharmaceutical distributors. The transaction structure typically consists of direct sales agreements where clients place orders for customized sterile drug batches, followed by comprehensive quality control and compliance documentation, ensuring high-quality standards that foster long-term partnerships.

Pharmidea plans to expand its product lineup by launching new sterile drugs tailored for various therapeutic areas by the end of 2025. The company is also looking to penetrate additional markets in Asia and the Middle East to enhance its global footprint. The funding obtained in June 2008 will be utilized to support these initiatives, including product development and market expansion efforts.